Welcome to our dedicated page for Airsculpt Technologies SEC filings (Ticker: AIRS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AirSculpt Technologies, Inc. filings document the regulatory record of a public medical aesthetics company that provides premium body contouring procedures. Its 8-K reports cover operating and financial results, preliminary updates, non-GAAP financial measures, reconciliations, debt and capital-structure disclosures, material agreements, and governance events.
Proxy materials describe annual meeting matters, director elections, shareholder voting items, board structure, and related governance disclosures. Other filings include late-filing notices tied to annual report timing, amendments correcting non-GAAP presentation, and emerging growth company status under SEC reporting rules.
AirSculpt Technologies, Inc. Schedule 13G discloses that Aaron Rollins beneficially owns 14,721,062 shares of the issuer's common stock. The filing states this represents 20.9% of the class, calculated using 70,545,681 shares outstanding as of May 7, 2026 per the company's Form 10-Q for the period ended March 31, 2026. The filing lists sole voting and dispositive power over the same 14,721,062 shares and is signed by Mr. Rollins on June 1, 2026.
Airsculpt Technologies, Inc. disclosed that an entity associated with major holder Adam T. Feinstein reported an internal share transfer involving its common stock. On May 20, 2026, EBS Aggregator Blocker Holdings, LLC made a distribution in-kind of 5,169,820 shares of common stock for no consideration to Thrivent White Rose Fund XI Equity Direct, L.P., under a prior letter agreement. The filing characterizes this as an "other" type transaction rather than a market purchase or sale. Following the reported transactions, indirect holdings include 4,523,899 shares by Vesey Street Capital Partners Healthcare Fund-A, LP, 14,038,819 shares by VSCP EBS Aggregator, L.P., and 6,591,642 shares by EBS Aggregator Blocker Holdings, LLC.
Higgins Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Airsculpt Technologies, Inc. director Kenneth Higgins received an award of 100,286 shares of Common Stock in the form of Restricted Stock Units on May 12, 2026. These RSUs vest on the earlier of the first anniversary of grant or the day before the next annual stockholder meeting, subject to his continued service with the company.
Following this award, Higgins directly holds 274,066 shares of Airsculpt Technologies Common Stock as reported in the filing.
Aaron Thomas J reported acquisition or exercise transactions in this Form 4 filing.
Airsculpt Technologies director Aaron Thomas reported receiving a grant of 100,286 shares of Common Stock in the form of Restricted Stock Units on May 12, 2026. This is a compensation-related award at no cash cost per share, not an open-market purchase.
The RSUs will vest upon the earlier of the first anniversary of the grant date or the day before the next annual meeting of stockholders, provided he continues serving the company. Following this grant, Thomas holds 276,866 shares directly, showing this is a sizeable but routine equity award for a director.
Airsculpt Technologies, Inc. director Caroline Chu received an equity grant in the form of restricted stock units. She was awarded 100,286 shares of Common Stock on May 12, 2026 as a grant/award acquisition at a stated price of $0.00 per share, reflecting stock-based compensation rather than a market purchase.
According to the filing, her direct holdings increased to 277,066 shares of Common Stock after the award. The RSUs will vest upon the earlier of the first anniversary of the grant date or the day prior to the next annual meeting of stockholders, contingent on her continued service with the company.
AirSculpt Technologies, Inc. held its 2026 annual stockholder meeting virtually on May 12, 2026. A total of 65,895,278 shares of Class A common stock were present or represented by proxy, which was 93.49% of the 70,486,528 shares entitled to vote as of March 13, 2026.
Stockholders elected three Class II directors—Adam Feinstein, Thomas Aaron, and Kenneth Higgins—to serve until the 2029 annual meeting. Each nominee received more than 33.8 million votes "for," with broker non-votes reported on this proposal.
Stockholders also ratified the selection of Grant Thornton LLP as the company’s independent registered public accounting firm for the year ending December 31, 2026, with 41,551,299 votes for, 24,343,978 against, and 1 abstention. No other matters were submitted for a vote.
AirSculpt Technologies, Inc. reported essentially flat performance for the three months ended March 31, 2026, generating revenue of $39.4 million on 3,082 cases, similar to $39.4 million and 3,076 cases a year earlier. Revenue per case was stable at about $12,780.
The company posted a net loss of $2.4 million, modestly better than the $2.8 million loss in 2025, while Adjusted EBITDA declined to $3.3 million, an 8.4% margin versus 9.5% a year ago, reflecting higher selling, general and administrative costs.
AirSculpt strengthened its balance sheet by raising approximately $14.6 million through its at-the-market equity program and voluntarily prepaying $10.0 million on its term loan, reducing total debt, net, to $44.8 million. Cash and cash equivalents increased to $16.7 million, and management concluded there is no substantial doubt about the company’s ability to continue as a going concern. However, previously disclosed material weaknesses in internal control over financial reporting, including general accounting processes and lease accounting under ASC 842, remained unremediated as of March 31, 2026.
AirSculpt Technologies reported first-quarter 2026 results with stable revenue and a smaller loss. Revenue was $39.4 million, essentially flat with the prior-year quarter, while case volume edged up to 3,082 and same-center sales increased 1%.
Net loss improved to $2.4 million from $2.8 million, and Adjusted EBITDA declined to $3.3 million from $3.8 million, with an Adjusted EBITDA margin of 8.4%. The company reaffirmed full-year 2026 guidance for revenue of approximately $151 to $157 million and Adjusted EBITDA of approximately $15 to $17 million. Cash and cash equivalents rose to $16.7 million as of March 31, 2026, aided by $14.6 million raised under an at-the-market equity program and $11.4 million of debt repayment, reducing long-term debt while maintaining compliance with all covenants.
Airsculpt Technologies, Inc. amendment reports Parian Ultreia beneficially owns 6,744,000 shares (9.6%). The Schedule 13G/A (Amendment No. 2) lists Parian Ultreia as a Delaware filer holding 6,744,000 shares with sole voting and dispositive power. The filing is signed by Portfolio Manager Zachary Miller and dated 04/21/2026.
Airsculpt Technologies, Inc. insider Jorey Chernett reported an open-market purchase of 40,000 shares of Common Stock at a weighted average price of $2.54 per share. After this transaction, Chernett directly owns 7,053,761 Common Stock shares. The filing notes the shares were bought in multiple trades between $2.52 and $2.56.
The filing also reports the expiration of short call option positions on Airsculpt common stock. Call options on 200,000 underlying shares with a $5.00 exercise price and on 200,400 underlying shares with a $4.00 exercise price expired unexercised because the market price was below the exercise prices, and no consideration was received in connection with these expirations.